Vitamin K

Chapter 136 Vitamin K

imageForms, Sources, Absorption, and Metabolism

Forms: K1, K2, and K3

The currently known forms of vitamin K can be grouped in three categories: vitamin K1 (one type), vitamin K2 (14 types), and vitamin K3 (one type) (Figure 136-1). Vitamins K1 and K2 are fat-soluble, whereas vitamin K3 is water-soluble.1 Technically, only vitamin K1 is recognized as a true vitamin, essential for human and animal well-being. Vitamins K2 and K3 can be derived as metabolites of vitamin K1 in various tissues or the gastrointestinal tract in animals or humans. However, there may be many clinical situations that can benefit from supplementation with vitamin K2 (from diet and/or supplements) or from the intravenous administration of vitamin K3. Oral vitamin K3 is used only in animal nutrition; for humans, it is currently allowed only for research purposes.2

The structures of vitamins K1, K2, and K3 are similar in regard to their core molecule, called menadione (or 2-methyl-1,4-naphtoquinone). Vitamin K3 is simply composed of the core molecule menadione (see Figure 136-1, C), whereas vitamins K1 and K2 contain the core molecule menadione plus specific side chains that distinguish them as follows3:

Vitamin K1 is hydrophobic but not very lipophilic, whereas all vitamin K2 forms become increasingly more lipophilic as the length of their side chains increases, which is relevant for their different rates of absorption and metabolism.

On average, it is estimated that 80% to 90% of dietary vitamin K intake is typically derived from vitamin K1, with the rest coming from vitamin K2.4

Main Aspects of Vitamin K1 (Phylloquinone or Phytomenadione)

Vitamin K1, also called phylloquinone or phytomenadione, is synthesized only by plants or algae, where it is bound in the thykaloid membranes of chloroplasts and participates in the electron transport chain of photosynthesis. Vitamin K1 occurs in significant amounts (50 to 800 mcg/100 g food) in certain vegetables, vegetable oils, seeds, algae, and in small amounts (<50 mcg/100 mcg food) in the rest of the vegetable and animal foods, as listed in Figure 136-2. See Table 136-1 for the typical yield of vitamin K1 in common measures of select vegetables, which are the most significant sources of vitamin K1 of all vegetable foods.

Vitamin K1 is also available for oral or intramuscular injection to correct clotting deficiency in newborns or to compensate for anticoagulant overdose in adults. Studies are conflicting in regard to the concern that vitamin K1 injection may increase the risk of various cancers, including leukemia in infants. Recent research seems to have established that the risk was related to the route of administration, specifically to injection and not via the oral route. Also, the safest and most reliable way to increase vitamin K1 in the unborn fetus and reduce the risk of bleeding after birth seems to be by increasing the mother’s vitamin K status, as some studies suggest.5


Absorption of vitamin K1 varies considerably depending on its source. When it is delivered in a vegetable, its bioavailability is low (3% to 10%) because it is trapped in the chloroplast.6 Cooking and/or mechanical processing (blending, juicing) of the vegetables or pressing the oil out of the vegetable seeds (such as sunflower seeds) increases the vitamin’s bioavailability and absorption up to as much as 50% as compared with the raw vegetable.7

By adding dietary fat to the vitamin K1-containing food, absorption of the vitamin can be doubled; it may then reach 10% to 15%.8 Following is a summary of estimated vitamin K1 absorption values, obtained by comparing a number of studies917:

Exposure to ultraviolet (UV) light inactivates vitamin K. When oils containing vitamin K1 are hydrogenated (during industrial processing, cooking, frying, or baking), a big percentage (40% to 50%) of the vitamin K1 content is also hydrogenated. Studies have shown that hydrogenated vitamin K1 has very little biological activity.18 It is important to note that a large section of the population derives a majority of its vitamin K1 from vegetable oils as opposed to vegetables, so the effect of vitamin K inactivation by hydrogenation may have an important impact on common deficiencies of vitamin K, which may be higher than estimated from just vitamin K1 intake surveys.

Transport, Metabolism, and Distribution in Human Tissues

Once ingested, vitamin K1 can be metabolized through various routes in the body (see Figure 136-2).

Vitamin K1 is transported initially in the chylomicrons through lymph and blood to the liver and other tissues. Once taken up by various tissues, vitamin K1 may be stored and utilized unchanged, while part of it may be converted to K2 (MK-4). For unclear reasons, the steady-state ratio of K1/K2 (MK-4) stored in each tissue seems to be specific to each tissue. See Figure 136-2 for a list of these ratios in various tissues and organs.19

One study estimates that 5% to 25% of the absorbed vitamin K1, the same as various K2 forms, is converted to K3 in the intestinal cells.20 Various cells in the body may take up vitamin K3 and convert it to vitamin K2 (MK-4). A portion of vitamin K3 is converted to K2 (MK-4) in each tissue.21

Part of the ingested vitamin K1 is taken up by certain types of gastrointestinal bacteria (Bacteroides, Escherichia coli, and Propionibacterium) and converted into vitamin K3 or into vitamin K2 (MK-n, n = 1 to 14), the most predominant forms being the longer-chains MK-7, 8, 9, 10, and 11.

As a result of uptake in all the metabolic pathways described previously, vitamin K1 intake can lead to an increase of various forms of vitamin K in the body, as follows: vitamin K1 in serum and tissues, vitamin K3 especially in the serum, vitamin K2 (MK-4) in the tissues, and long-chain K2 especially in the liver.

One study looked at the vitamin K stored in the rat brain in response to supplementation with either vitamin K1 or vitamin K2 (MK-4).20 Contrary to what was expected, the results showed that supplementation with vitamin K1 was able to increase the brain content of K2 (MK-4) more than direct supplementation with vitamin K2 (MK-4).

Main Aspects of Vitamin K2

A Family of Menaquinones: K2 (MK-1) through K2 (MK-14)

Vitamin K1 Conversion to Vitamin K2 (MK-4): Tissue Distribution of Vitamin K1 versus Vitamin K2 (MK-n), n = 1 to 14

Vitamin K2 (MK-4) is the most prevalent form of vitamin K in human and animal tissues, at about 90% of total vitamin K stored, with the remainder as mostly vitamin K1 and small amounts of long chain K2 (MK-n)s (n = 7 to 11).

The distribution of K1 versus K2 in animal tissues is quite variable. For unknown reasons, the steady-state ratio of K1/K2 (MK-4) stored in each tissue seems to be specific to that tissue.

Many studies have shown that various long-chain K2 (MK-n)s are converted to K2 (MK-4) in all tissues with the exception of the liver. For example, dietary supplementation with K2 (MK-7) from natto was shown to result in a significant increase of K2 (MK-4) in bone, whereas no MK-7 was detected in the bone.23

A substantial amount of long-chain K2 [MK-n]s, n = 7 to 11 is stored in the liver unchanged, and this organ has a distinct distribution of vitamin K compared with all other tissues: that is, 90% long-chain menaquinones (K2[MK-n]s, n=8 to 11) and 10% vitamin K1. This may be because the liver is the first organ to have access to the vitamin K2 synthesized by the intestinal bacteria, which is absorbed through the lower ileum. This preferential sequestering of MK-ns in the liver is hypothesized to be an evolutionary adaptation for securing a low-turnover vitamin K pool to support clotting needs and protect against the dietary variability of vitamin K1 or K2 (MK-4).

Dietary Sources of Various Forms of Vitamin K2

Dietary sources of various forms of vitamin K2 (various menaquinones) include animal meats and dairy as well as fermented foods of animal or vegetable origin, as follows:

Animal Foods:

Meats (2 to 3 mcg/100 g), egg yolk (10 mcg/one egg), and milk. These sources preferentially provide the K2 (MK-4) form along with similar amounts of vitamin K1. See Table 136-2 for a listing of the vitamin K2 content of various foods. Table 136-2 lists the vitamin K2 content of select foods from three studies in the United States, Holland, and Japan.24

The content of vitamins K1 and K2 in human milk depends on the mother’s intake of these vitamins.25 The same may be true for cow’s milk and other animal milks. Similarly, the vitamin K content of animal tissues may be lower for animals fed mostly corn versus those that are exclusively grass-fed, although no studies have measured this. The vitamin K2 content of animal-derived food may be higher when they are supplemented with vitamin K3 (a common practice). Since vitamin K3 supplementation has proved detrimental for humans, it may be of questionable safety for animals. Also, continuous antibiotic treatment of the animals (to enhance growth) may impair their intestinal bacterial production of vitamin K2.

Main Aspects of Vitamin K3 (Menadione): Occurrence, Properties, and Special Considerations for Animal and Human Consumption

Vitamin K3 (menadione) has not been observed to occur in natural foods in any significant amount. It is believed to be formed inside intestinal cells and possibly other tissues and organs of humans and animals and can be found in the plasma and urine 2 to 3 hours following ingestion of either vitamin K1, K2 (MK-4), or K2 (MK-7). Certain intestinal bacteria can convert the ingested vitamin K1 to K3 or de novo synthesize vitamin K3 from compounds such as alpha-keto-glutarate.

Vitamin K3 is not a vitamin in the true sense; initially it was synthesized to be used as an oral provitamin K compound, most likely because of its conversion to vitamin K2 (MK-4) in human and animal tissues.

Vitamin K3 may have been chosen as a supplement because it is a much simpler molecule to synthesize than vitamins K1 or K2; thus it was less expensive to produce. However, oral consumption of vitamin K3 was banned in humans when various side effects were noticed, such as increased red blood cell lysis, excessive oxidative stress, and nonspecific binding of thiols from large and small molecules in the blood.

However, the cytotoxic effects of vitamin K3 were recognized as useful in support of cancer treatment, alone or in addition to chemotherapy, and K3 has been used in the oral and intravenous forms (discussed later) in research studies involving humans. Vitamin K3 is not currently available as a drug or supplement for human use.

It is important to keep in mind that serum vitamin K3 can rise significantly as a result of ingesting supraphysiologic doses of vitamins K1 or K2 (above 1 mg), especially if given in one bolus. (This concern is discussed under “Potential Side Effects of High Doses of Vitamins K1, K2, and K3”).

imagePhysiologic Roles of Vitamin K: Effects of Normal to Supraphysiologic Doses

Mechanisms of Action of Vitamins K1 and K2

Aside from blood clotting support, new research is revealing numerous roles for vitamin K in many tissues and organs through a variety of mechanisms.

Vitamin K’s actions in human physiology are very complex:

Vitamin K activates a variety of VKDs throughout the body by carboxylating a specific number of the glutamatic acid residues they contain, which become, as a result, gamma-carboxyglutamate residues, also called Gla. One molecule of vitamin K1 or K2 can be recycled many times, so it is used multiple times to produce Gla residues before it is metabolized for elimination (Figure 136-3).

Once carboxylated, these residues can bind calcium or interact with cell membranes more efficiently. The more glutamate residues are carboxylated on a VKD protein, the better its functionality. Ultimately, the more vitamin K is available in the body, the higher the percentage of fully carboxylated VKDs will be.

Until now, the AI (adequate intake) for vitamin K has been defined as the amount needed to completely carboxylate prothrombin. With the discovery of new roles for various VKDs throughout the body, many researchers are now proposing redefining the AI at a level where all VKDs in the body are 100% carboxylated. A review by McCann and Ames points out that vitamin K affinity varies greatly for each type of VKD, which may influence the order in which VKDs are carboxylated. Most likely, this is done in an order of physiologic priority.29 For example, clotting may have the highest priority in utilizing most of the vitamin K ingested when intake is around or below 100 mcg/day. In this situation, most of the other VKDs in the body will tend to be inadequately carboxylated and so have poor functionality. Unfortunately, there are no tests to verify the carboxylation of all the known VKDs except for the three that will be discussed (PIVKA II, osteocalcin, and MGP). Important cofactors affecting the rate of carboxylation of VKDs are manganese and vitamin B6, specifically P5P (pyridoxal-5-phosphate). Deficiency of these cofactors may downregulate carboxylation, whereas supplementation with P5P was shown in vitro to upregulate it twofold.

Osteocalcin is a protein produced by osteoblasts (bone-building cells) that transports calcium inside the bone for fixating it in the hydroxyappatite structure, thus supporting bone mineralization. Vitamin K has been shown to stimulate osteoblasts to increase their production of osteocalcin and collagen type I, both important components of the bone structure. Increased levels of osteocalcin are able to better support bone remodeling and thus improve bone architecture, which translates into better bone elasticity and reduced risk of fracture.3032

Osteodentin (tooth dentin) is responsible for tooth mineralization, similar to osteocalcin’s role in the bone.33 Note that the salivary gland concentrates a significant amount of vitamin K, which may have a role in supporting oral health. Vitamin K is known to affect certain bacteria by participating as a cofactor in their energy production (similar to coenzyme Q10 in animal mitochondria). If it is in fact proved that salivary glands secrete vitamin K, this would affect oral bacteria; one researcher has stated that excess vitamin K may exacerbate periodontal disease.34

Nephrocalcin is found in kidney tissue and is believed to support calcium ion solubilization and inhibit crystal nucleation, thus reducing the risk of kidney stones.

Matrix Gla protein, or MGP, is found in many soft tissues, where it has at least one identified role, that of rejecting calcium deposition. Specifically, it is found in the skin and in the walls of arteries and veins, where it prevents the calcification of elastin fibers, thus reducing the risk of elasticity loss in these tissues. It is also found incorporated with underlying ground substance of the skin and cartilage (associated with chondrocytes), where it seems to play a role in the synthesis of glycosaminoglycans.35 MGPs have also been identified in testes and sperm; their role there is not clear, but vitamin K deficiency has been shown to reduce testosterone production and sperm motility. One study that looked at primary prostate cancer cells versus metastatic cells found that “loss of MGP expression may be associated with tumor progression and metastasis.”36

Note here the important roles of vitamins D and A in some of these VKDs:

Consequently vitamins K, D, and A work in concert and have interdependent actions. Thus, in order for vitamin K to perform its functions, the status of vitamins D and A must be optimized, so that VKDs are expressed adequately. It has also been established that the genetic effects of 1,25(OH)D3 are mediated by vitamin A through its nuclear receptor, which exert a permissive activation on the vitamin D nuclear receptor.39

GAS-6 protein (growth arrest-specific gene 6) is believed to play a role in platelet aggregation, cell growth, and apoptosis and has been shown to support the survival of cells in tissues such as arterial muscle, eye lens epithelium, brain, and possibly others. It is also involved in supporting adequate innate immunity (natural killer [NK] cells) and reducing the risk or severity of autoimmune cellular events.40

Modulation of Inflammation by Downregulation of Inflammatory Cytokines

Vitamin K may reduce inflammation by downregulating of IL-6 and PGE2 as follows:

These actions of vitamin K may reduce the activity of any inflammatory/autoimmune diseases that are exacerbated by PGE2 and IL-6.43 In osteoporosis, IL-6 and PGE2 have been shown to enhance bone resorption through activation of the RANKL receptor, which in turn upregulates osteoclast differentiation.44 This mechanism is considered essential to the effects observed from treatment with high doses of K2 (MK-4) in reducing and reversing bone loss. Vitamin K2 has also been shown to reduce the activity of rheumatoid arthritis by inhibiting the proliferation of the rheumatoid synovial cells.45 A correlation has been found between vitamin K status (plasma vitamin K1) and osteoarthritic disease activity in the hands and knees.46 In the Framingham study, plasma vitamin K1 was shown to inversely correlate with C-reactive protein (CRP), a marker of inflammation.

An elevated PGE2 should also be corrected by addressing the arachidonic acid/eicosapentaenoic acid (AA/EPA) ratio. This, in effect, modulates the substrates of the COX2 enzyme and would have an additional impact on PGE2 production when added to the effect of vitamin K2 (MK-4) of inhibiting COX2. One study states the effect of the AA/EPA ratio on another inflammatory intermediate as follows: “nuclear factor kB is activated by arachidonic acid but not by eicosapentaenoic acid.”47

Downregulation of Cell-Signaling Proteins (Produced Downstream of Mevalonate and HMG-CoA) Affecting Cell Differentiation and Apoptosis

Vitamin K2 (MK-4) is believed to have an inhibitory effect in pathways downstream of mevalonate, the same pathways where statins and bisphophonates are believed to inhibit key enzymes (HMG-CoA reductase and protein farnesyl transferase, respectively). However, the actions of K2 (MK-4) are not the same as those of pharmaceutical drugs, which have a direct enzyme inhibitory action. Instead, K2 (MK-4) seems to work through a feedback inhibition effect on the mevalonate pathway by “mimicking” one of its downstream metabolites, the molecule geranylgeranyl pyrophosphate.48,49 This mimicry occurs by means of the side chain of vitamin K2 (MK-4), which is the molecule geranylgeranyl. This may be why K2 (MK-4) has distinct effects compared with those of other forms of vitamins K2 or K1.

The inhibition of the mevalonate pathway has multiple effects on human physiology besides cholesterol inhibition since it also downregulates the synthesis of various geranylgeranylated proteins (rho, rab, rac) involved in cell proliferation, cell death, and survival, inflammation, and immune response.50 Consequently when vitamin K2 (MK-4) is supplied orally in large doses (many studies have used 45 mg and even 90 mg,51 which are in the supraphysiological range), it exerts a “mass action” characterized by some researchers as “pharmacologic” in nature.

K2 (MK-4) has been used as a drug in Japan and as a therapeutic nutrient in the United States for the prevention or reversal of osteoporosis, prevention or reversal of cardiovascular calcification, cancer prevention, and treatment support.

In conclusion, vitamin K as K1 or K2 is being revealed to have a plethora of actions and specific benefits for health maintenance and disease prevention or treatment.

Roles in Bone Health and Therapeutic Interventions for Osteoporosis

Bones undergo continuous remodeling by two opposing processes: (1) bone building by osteoblast cells and (2) bone breakdown (or bone resorption) by osteoclast cells. Vitamins K1 and/or K2 modulate bone metabolism through similar mechanisms, but vitamin K2 has additional effects that vitamin K1 cannot exert directly:

1. Vitamins K1 and K2 are cofactors for the activation (by carboxylation) of osteocalcin, which enables the proper deposition and binding of calcium in the bone matrix.

2. Osteoblasts’ production of osteocalcin and collagen type I is increased by vitamin K2 through modulation of the genetic expression of these proteins.52

3. Vitamin K2 reduces osteoblasts’ apoptosis (cell death)53 and stimulates other bone blastic proteins, such as osteoprotegerin and osteopontin.54

4. Vitamin K2 reduces osteoclasts’ production from bone marrow cells55 and induces osteoclasts’ apoptosis, which in effect reduces the total number of osteoclasts. These metabolic effects are achieved through vitamin K2’s ability to downregulate inflammation (IL-6, PGE2) and cell proliferation while increasing apoptosis (through the geranylated proteins produced on the mevalonate pathway).56 This would be beneficial only if the osteoclastic activity were excessively high.

5. Vitamin K2 may reduce the accelerated bone resorption induced by menopausal hormonal loss57 or corticosteroid treatment.58,59

The result of the combined actions of vitamins K1 and K2 is an optimization of calcium incorporation in the bone matrix and, at the same time, because of K2 activity, a reduction of excessive bone breakdown (bone resorption). Bone resorption is a necessary process for optimal bone renewal, but it may be detrimental if it is excessive, as in the case of increased inflammation (PGE2, IL-6), increased metabolic signals from geranylated proteins (produced downstream of mevalonate), or deficiency of certain hormones (menopause/andropause: low estrogen, low progesterone, low testosterone).

Vitamin K Doses in the Physiologic Range

Some studies that tested interventions for bone health have used doses of vitamin K that can be considered physiologic—for example, 200, 500, and 1000 mcg of K1.31 The optimal physiologic range has not been completely defined for vitamin K1 and less is known about that of vitamin K2. The dose needed for complete bone osteocalcin activation is believed to be around 1000 mcg of K1, but some individuals may need 2000 mcg.60 This dose is 10 to 20 times higher than that needed for optimal clotting, which is in the range of 90 to 120 mcg.61 In this dosage range, vitamin K exerts its effects in the metabolic pathways, the way the human body evolved to utilize this nutrient. Owing to very low consumption of leafy greens or liver, most people rarely ingest more than 100 to 200 mcg of vitamin K1 and more than 50 mcg of vitamin K2.114 Vitamin K doses in the “normal” physiologic range would most likely be effective, as some studies have shown,62 for the prevention of osteoporosis or osteopenia.

Vitamin K Doses in the Supraphysiologic Range

Therapeutic doses of vitamin K2, such as 45 mg of K2 (MK-4) or 5 and 10 mg of K1, have been used for aggressive intervention in attempts to reverse already established osteoporosis or osteopenia or to reduce the rapid bone loss typical of menopause without hormone replacement therapy (HRT) or due to corticosteroid treatment. This approach most likely takes advantage of a “mass action” effect of vitamin K in certain biochemical pathways. These high doses of vitamin K could not be attained by any realistic diet.

Most of the studies using a very high daily dose of K2 (MK-4) (e.g., 45 mg) done in Japan with the drug version of K2 (MK-4), Glakay, have shown a significant effect on bone mineral density (BMD). The differences in BMD changes between the treatment and placebo groups for BMD were as follows: +1.1%, +5.2%, and +7.5% after 6, 12, and 24 months, respectively. Some studies also reported a reduced fracture rate (FR) by as much as 80%. Some studies have shown that vitamin K can reduce the FR even when BMD is not affected.63

However, in two recent studies conducted in Holland and the United States, where the investigators used the same K2 (MK-4) material from Japan (Glakay), there was no effect on BMD.64,65 At least the Dutch study found an increase in total bone mineral content as a result of this treatment as well as in bone strength (calculated value). Also puzzling is the fact that a Glakay 1996 postmarketing population survey done in Japan of 4000 people taking the same dosage of 45 mg/day of K2 (MK-4) showed no effect on overall FR (however, a subgroup that had at least five fractures at baseline did show a fracture reduction of about 40%).66 BMD was not assessed in this survey.

Only a few of the studies that used vitamin K1 (in daily doses of 200 and 1000 mcg) have seen a higher BMD in the treatment group over placebo. However, others that used daily doses of 500 mcg, 1 mg, 5 mg, and 10 mg have found no effect on BMD, even though the doses of 5 mg and 10 mg were 5 and 10 times higher than the upper physiologic dose of 1 mg. None of the vitamin K1 studies mentioned previously reported FR except the one using 5 mg, which showed an approximate 50% reduction despite no change in BMD.62

Interestingly, a few of these studies included multiple treatment groups in addition to placebo in an attempt to sort out the effect of vitamin K alone or vitamin D alone versus combination treatments that included vitamin K plus vitamin D or vitamin D plus calcium or all three together.67,68 The results from all these studies clearly showed that combining vitamin K with vitamin D had a stronger effect than either one alone and that combining vitamin K with vitamin D and calcium had even stronger effects. Only one study added magnesium and zinc to the treatment group (taking vitamin K1 = 1 mg, vitamin D = 320 IU, and calcium = 500 mg), and this is one of the only two studies using vitamin K1 that showed a slower age-related decline in BMD in the treatment group.69

The potential reasons for some of the disappointing and conflicting results among all vitamin K studies may be explained by the following reasons but are not limited to them:

Vitamin K supplementation is believed to improve bone quality whether or not it shows effects on BMD.72 Bone quality may be best reflected by assessments of BU, BMC, BG, and BS; this has been done in a few studies in addition to the measurement of lumbar and spinal BMD.73,74 One interventional study with 45 mg of vitamin K2 (MK-4) has shown an increase in both BMC and BG despite no effect on BMD. The treatment group also maintained their bone strength (calculated from BMD and BG) as compared with the placebo group, which showed an expected age-related decline in bone strength. Consequently, this study showed that vitamin K supplementation might reduce FR even though it did not affect BMD.64

Researchers estimate that vitamin K status (as assessed by undercarboxylated Oc [ucOc] in plasma) may correlate better with BU and FR than BMD.63 Bone heel BU was found to have an accuracy and ability to discriminate osteoporotic patients similar to lumbar and spine BMD (by dual-emission x-ray absorptiometry, or DEXA), with potentially better prediction for FR. Consequently it may be useful to do a BU measurement (in addition to or instead of DEXA) in assessing the effects of vitamin K interventions in clinical practice. One study found that “ultrasound parameters were still significant independent predictors of vertebral fracture even after adjusting for BMD.”75 The BU test may give additional information to the BMD test, especially for patients who, for example, have increased their BMD after many years of bisphosphonate therapy (which reduces bone remodeling severely owing to its main mechanism of action of inducing osteoclast apoptosis).

The Synergy and Necessity of Combining Vitamins K and D

Vitamin D is known to enhance Oc expression. It was also demonstrated in vitro that the active form of vitamin D (1,25[OH]D3) enhances the effect of vitamin K2 on Oc.78 Vitamin K cannot realize its potential to carboxylate Oc if Oc is not adequately expressed in the first place owing to low vitamin D status.79

None of the studies employing vitamin K1 or K2 supplementation optimized the vitamin D status (as assessed by plasma 25[OH]D3) with sun exposure or vitamin D supplementation. Most studies used insufficient doses of vitamin D in the range of 200 to 1000 IU, whereas some used an analog of an active form of vitamin D: 1-alpha-hydroxycholecalciferol (which has drug status in Japan). Many commercial laboratories have raised the upper limit of the reference range to include the whole “normal physiologic range.” The upper limit of the new reference range of plasma 25(OH)D3 now corresponds to adequately sun-exposed individuals (the so called “lifeguard level”), which has effectively almost doubled the old upper limit of the reference range. The old limit was simply derived from a population that was not adequately exposed to sun.80

The studies that used slightly higher doses of vitamin D, such as 800 or 1000 IU, achieved some of the better results: (1) FR reduction of about 50% (with 5 mg K1 and 800 IU of D3)63 and (2) a BMD increase of 2.3% over baseline and a 7.35% increase over placebo when supplemented with 45 mg of K2 (MK-4), 1454 mg of calcium, and 1000 IU of vitamin D2. They showed that the higher the baseline levels of 25(OH)D3, the higher the rate of BMD increase was in the treatment group. Also, the lower the baseline levels of 25(OH)D3 were, the faster the BMD decline was in the untreated group.

The reason this study used D2 was stated by the authors as lack of availability of vitamin D3 in Japan at that time (2005). Vitamin D2 compared to vitamin D3 is similar but not as effective. In fact, the researchers believed that had they used D3, the results might have been stronger, and a recently published paper shows that vitamin D3 was 87% more effective in raising blood levels of vitamin D and also resulted in a two- to threefold increase in vitamin D storage as compared with D2.81

One animal study, published in 1994 and funded by the drug company producing Glakay (K2[MK-4])155, demonstrated that vitamin K supplementation had no effect on the bone density in the vitamin D deficient rat group, but showed an increase in bone density in the group supplemented with vitamin D, which also ended up with 50% higher plasma levels of 25(OH)D3. However, no study attempted to raise plasma levels of 25(OH)D3 adequately, and it may be possibly because the doses necessary to achieve this, such as 2000 to 5000 IU of vitamin D3 per day, are still considered above the commonly accepted UL (upper tolerable limit).

Two study authors actually state in their papers that they purposely did not design the vitamin K studies with added doses of vitamin D above 400 IU because vitamin D3 supplementation at the level of 800 IU was able to show a reduction in bone fractures on its own and confounded the effects of vitamin K.82 Unfortunately, owing to this reductionist study design, we have few studies investigating the full effects of synergistic combinations of nutrients at levels that occur in a natural and optimal human physiology and in evolutionary adequate diets with added sun exposure.

Why Use 45 mg K2 (MK-4) and Are There Any Potential Side Effects?

It is also not clear why the makers of Glakay picked the particular therapeutic dose of 45 mg of K2 (MK-4) per day for most of their studies. No side effects have been observed so far from the usage of vitamin K2 (MK-4) under the pharmaceutical drug name Glakay since it was introduced in Japan in 1995 or in the many studies that employed it (including the postmarketing survey of 4000 subjects published in 2005). However, it is conceivable that there could be side effects from supraphysiologic doses of K2 (MK-4) that have not been detected so far because they would require more sophisticated testing than what was performed in these studies and in the population surveys. Here are some potential consequences of high-dose K2 (MK-4) based on its conversions and mechanism of action:

Special attention should be paid to patients who are on statin therapy, since this obviously inhibits HMG-CoA reductase and reduces all the downstream metabolites, including the one where K2 (MK-4) exerts a feedback inhibition on geranygeranyl pyrophosphate (as also discussed under “Mechanisms of Action of Vitamins K1 and K2”).

How Does K2 (MK-4) Compare with Bisphosphonates and Does It Make Sense to Combine Them?

One Japanese study showed that combining K2 (MK-4) supplementation with BP treatment showed an additive and synergistic effect, probably because of their complementary actions, such as bone building support by vitamin K and not just osteoclast apoptosis by BPs.83,84 Another study showed that vitamin K2 (MK-4) improved the effect of the BP in reducing FR significantly (slightly more than 50%) but had only a modest effect in improving BMD. Overall, BPs seem to have a much stronger effect in increasing BMD than K2 (MK-4). However, BPs seem actually to produce an increase in certain types of FR after long-term use.85 Also, as discussed in Chapter 194, “Osteoporosis,” although bisphosphonates increase BMD, such bones are less remodeled and seem to be less elastic and more brittle and therefore, with time, tend to become more vulnerable to fracture.

What Is the Potential of K2 (MK-7) in Supporting Bone Health?

The amount of total vitamin K2 (mix of various lengths) in a Western diet (from a sample Dutch population) (which may contain fermented cheese, fermented milk, and processed meats) averages 29 mcg/day (in a range from 1 to 128), from which K2 (MK-7) represents an average of 0.4 mcg (in a range from 1 to 2.2) (Table 136-3). Vitamin K2 intake is much higher in the Asian diet owing to its high content of fermented vegetables and soy-based fermented foods; it ranges from 35 to 247 mcg/day, of which K2 (MK-7) can represent 50 to 100 mcg/day in those that consume natto.

K2 (MK-7) is considered a candidate for supplementation to improve bone health because studies have shown a positive correlation between the levels of natto intake (a fermented soy and rice food) and various markers of bone health, such as the degree of carboxylation of OC, BMD, and FR.86 However, the benefits of natto may not be attributable entirely to its vitamin K2 content, as it also contains soy isoflavones, which may have a significant effect on bones in menopausal women that do not take hormonal replacement. Soy foods also contains minerals, and other nutrients.

A study supplementing adolescents with 45 mcg of K2 (MK-7) reported a drop in undercarboxylated Oc from approximately 48% to 38%, clearly showing that the 45-mcg of dose of K2 (MK-7) was not high enough to support the complete carboxylation of Oc.87 Researchers chose this dose because it had enough of a safety profile to be proposed as a supplement for adolescents, as it is within the normal range of total dietary vitamin K2 in Holland. However, dietary K2 is a mix of various forms of vitamin K2, of which K2 (MK-7) may represent only a small percentage, depending on diet (high in Japan; low in Holland and the United States). This level of 45 mcg of a vitamin K2 mix from a Dutch diet was found to best correlate with reduced arterial calcification and reduced risk of cancer in previous epidemiologic studies (discussed under “Role in Cardiovascular Health and Therapeutic Interventions for Reversing Arterial Calcification”). There is an ongoing study using 180 mcg of K2 (MK-7) investigating its effect on bone and arterial health, with results due in 2011.88

A 6-week study showed that a dose of K2 (MK-7)—147 mcg—was able to carboxylate Oc to a larger extent than an equimolar dose of vitamin K1 (100 mcg).89 However, at the end of this study, the percentage of ucOc was 23%, which is still higher than optimal.

The only conclusion that can be drawn from the comparison study with vitamin K1 is that the optimal K2 (MK-7) dose for Oc carboxylation is lower than the molar equivalent of K1. There may be specific benefits to using a small amount of K2 (MK-7) in a supplement regimen along with K1 and K2 (MK-4) because it converts slowly in the body to K2 (MK-4). This provides an advantage, because K2 (MK-7) could be a time-released source of K2 (MK-4). In summary, vitamin K2 (MK-7) may be best used in conjunction with the other forms of vitamin K at doses comparable with the traditional Japanese consumption values of up to 165 mcg/day.

Sep 12, 2016 | Posted by in MANUAL THERAPIST | Comments Off on Vitamin K
Premium Wordpress Themes by UFO Themes